With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (EDIT -0.66%) to rise from their current price near $10 to reach$16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump. It could happen. Here's why. This company just got a huge ...